News Column

Nuvilex Could Target Breast Cancer in Future Clinical Trial

May 30 2013 12:00AM

Marketwire

Tracker

BALTIMORE, MD -- (Marketwired) -- 05/30/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, believes that based on the results of two separate canine mammary studies, Nuvilex, Inc. (OTCQB: NVLX) could target breast cancer in a future clinical trial. The Company is an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients.

Nuvilex affiliate SG Austria conducted Phase I/II clinical trials in dogs with spontaneously occurring mammary tumors and results of the study were remarkably similar to its well-known human Phase II pancreatic cancer trial. Therefore, it is evident that the results of this animal trial could lead to a future human breast cancer clinical trial using the Company's live-cell encapsulation platform. Each year, over 200,000 women in the U.S. are diagnosed with breast cancer and over 40,000 deaths are caused by the disease.

On the surface it would seem incongruent that a mammary trial involving dogs and a human breast cancer trial would have a direct correlation. However, further due diligence confirms that a similar Purdue University research study in dogs that was funded by the U.S. Department of Defense demonstrated that such a study could clearly be used as a model for breast cancer treatment.

Nuvilex's two oncology trials clearly illustrate the potential efficacy in using encapsulated cells with a pro-drug as a targeting device for the treatment of solid pancreatic and mammary tumors. Moreover, the dog trial results will likely carry meaningful weight in determining the timing of the engagement of a breast cancer trial, as the Purdue trial confirmed the substantial correlative value of dog trial results. As a result, Nuvilex, Inc. (OTCQB: NVLX) could be viewed as a two-headed oncology treatment entity, rather than a firm with a single, proven oncology indication in its arsenal.

A copy of this article as well as other articles and Nuvilex reports can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.



Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com





Source: Marketwire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters